Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022-Reference-Cited by-同舟云学术

Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022

Published:2024-02-14 Issue:4 Volume:29 Page:355-362
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Ichihara Eiki^ORCID,Ochi Nobuaki,Makimoto Go,Kudo Kenichiro,Harada Daijiro,Ozaki Yukinori,Nishio Hiroshi,Tsuchihashi Kenji,Miura Yuji,Endo Makoto,Yano Shingo,Maruyama Dai,Yoshinami Tetsuhiro,Susumu Nobuyuki,Takekuma Munetaka,Motohashi Takashi,Ito Mamoru,Baba Eishi,Uchino Keita,Kimura Takahiro,Kamiyama Yutaro,Nakao Shinji,Tamura Shinobu,Nishimoto Hitomi,Kato Yasuhisa,Sato Atsushi,Takano Toshimi,Kubo Toshio

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02469-4.pdf

Reference21 articles.

1. Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/CAAC.21660

2. Soria J-C, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 378:113–125. https://doi.org/10.1056/NEJMOA1713137

3. Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 377:829–838. https://doi.org/10.1056/NEJMOA1704795

4. Shaw AT, Ou S-HI, Bang Y-J et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971. https://doi.org/10.1056/NEJMOA1406766

5. Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 375:1823–1833. https://doi.org/10.1056/NEJMOA1606774